e-5531 and Escherichia-coli-Infections

e-5531 has been researched along with Escherichia-coli-Infections* in 1 studies

Other Studies

1 other study(ies) available for e-5531 and Escherichia-coli-Infections

Article	Year
E5531, a pure endotoxin antagonist of high potency. Science (New York, N.Y.), 1995, Apr-07, Volume: 268, Issue:5207 Shock due to Gram-negative bacterial sepsis is a consequence of acute inflammatory response to lipopolysaccharide (LPS) or endotoxin released from bacteria. LPS is a major constituent of the outer membrane of Gram-negative bacteria, and its terminal disaccharide phospholipid (lipid A) portion contains the key structural features responsible for toxic activity. Based on the proposed structure of nontoxic Rhodobacter capsulatus lipid A, a fully stabilized endotoxin antagonist E5531 has been synthesized. In vitro, E5531 demonstrated potent antagonism of LPS-mediated cellular activation in a variety of systems. In vivo, E5531 protected mice from LPS-induced lethality and, in cooperation with an antibiotic, protected mice from a lethal infection of viable Escherichia coli. Topics: Animals; BCG Vaccine; Cytokines; Drug Design; Endotoxins; Escherichia coli Infections; Gram-Negative Bacteria; Humans; In Vitro Techniques; Lipid A; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Monocytes; Moxalactam; Nitric Oxide; Rhodobacter capsulatus; Tumor Necrosis Factor-alpha	1995

Article

Year

E5531, a pure endotoxin antagonist of high potency.

Science (New York, N.Y.), 1995, Apr-07, Volume: 268, Issue:5207

Shock due to Gram-negative bacterial sepsis is a consequence of acute inflammatory response to lipopolysaccharide (LPS) or endotoxin released from bacteria. LPS is a major constituent of the outer membrane of Gram-negative bacteria, and its terminal disaccharide phospholipid (lipid A) portion contains the key structural features responsible for toxic activity. Based on the proposed structure of nontoxic Rhodobacter capsulatus lipid A, a fully stabilized endotoxin antagonist E5531 has been synthesized. In vitro, E5531 demonstrated potent antagonism of LPS-mediated cellular activation in a variety of systems. In vivo, E5531 protected mice from LPS-induced lethality and, in cooperation with an antibiotic, protected mice from a lethal infection of viable Escherichia coli.

Topics: Animals; BCG Vaccine; Cytokines; Drug Design; Endotoxins; Escherichia coli Infections; Gram-Negative Bacteria; Humans; In Vitro Techniques; Lipid A; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Monocytes; Moxalactam; Nitric Oxide; Rhodobacter capsulatus; Tumor Necrosis Factor-alpha

1995